Cited by 401BRCA gene mutations in cancerPancreatic and Hepatic Oncology ResearchGenetic factors in colorectal cancer

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma

Open access

Holter, Spring, Borgida, Ayelet, Dodd, Anna, Grant, Robert, Semotiuk, Kara, Hedley, David, Dhani, Neesha, Narod, Steven, Akbari, Mohammad, Moore, Malcolm, Gallinger, Steven·2015·Journal of Clinical Oncology

DOI 10.1200/jco.2014.59.7401

Open this paper in CoChat — free account Open PDF

Abstract

Purpose: The main purpose of this study was to determine the prevalence of pathogenic BRCA1 and BRCA2 mutations in a consecutively ascertained clinic-based cohort of patients with pancreatic ductal adenocarcinoma and describe the clinical and family history characteristics. Patients and Methods: Unselected, consecutive, incident patients with pancreatic ductal adenocarcinoma were recruited at a single cancer center over a 2-year period. Participants provided blood for DNA analysis and cancer family history, and cancer treatment records were reviewed. DNA from all patients was analyzed by Sanger sequencing and multiplex ligation-dependent probe amplification for germline variants in BRCA1 and BRCA2. Results: Three hundred six patients were eligible for analysis. Pathogenic germline BRCA mutations were identified in 14 patients (4.6%; 95% CI, 2.2% to 6.9%), including 11 patients with a BRCA2 mutation and three patients with a BRCA1 mutation. Having a cancer family history that met genetic testing criteria of the National Comprehensive Cancer Network or the Ontario Ministry of Health and Long-Term Care or self-reporting as Ashkenazi Jewish was significantly associated with BRCA mutation carrier status (P = .02, P < .001, and P = .05, respectively). However, the majority of the BRCA mutation–positive patients did not actually meet these genetic testing criteria. Conclusion: Pathogenic BRCA mutations were identified in 4.6% of a large cohort of clinic-based patients. Considering the implications for family members of BRCA carriers, and possibly tailored chemotherapeutic treatment of patients, our finding has implications for broader BRCA genetic testing for patients with pancreatic ductal adenocarcinoma.

Integrity signals

Registry

Crossref · 10.1200/jco.2014.59.7401

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Easton, D. F., Ford, D., & Bishop, D. T. (1995) · PubMed Central · Cited by 1,602
Cancer risks in BRCA2 mutation carriers.
Olsson, H. (1999) · Journal of the National Cancer Institute · doi:10.1093/jnci/91.15.1310 · Cited by 1,404
Cancer Incidence in BRCA1 mutation carriers.
Thompson, D., & Easton, D. (2002) · Journal of the National Cancer Institute · doi:10.1093/jnci/94.18.1358 · Cited by 1,231
Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
Pennington, K. P., Walsh, T., Harrell, M. I., Lee, M. K., Pennil, C. C., Rendi, M. H., Thornton, A., Norquist, B. M., Casadei, S., Nord, A. S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2287 · Cited by 1,075
A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
Ashworth, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0812 · Cited by 872
Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene
Jones, S., Hruban, R. H., Kamiyama, M., Borges, M., Zhang, X., Parsons, D. W., Lin, J. C.-H., Palmisano, E., Brune, K., Jaffee, E. M., et al. (2009) · Science · doi:10.1126/science.1171202 · Cited by 826
International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer
Canto, M. I., Harinck, F., Hruban, R. H., Offerhaus, G. J., Poley, J.-W., Kamel, I., Nio, Y., Schulick, R. S., Bassi, C., Kluijt, I., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-303108 · Cited by 784
Population BRCA1 and BRCA2 Mutation Frequencies and Cancer Penetrances: A Kin–Cohort Study in Ontario, Canada
Risch, H. A., McLaughlin, J. R., Cole, D. E. C., Rosen, B. P., Bradley, L., Fan, I., Tang, J., Li, S., Zhang, S., Shaw, P. A., et al. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj465 · Cited by 678
Self-citation
Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.
Goggins, M., Schutte, M. E. M., Lü, J., Moskaluk, C. A., Weinstein, C. L., Petersen, G. M., Yeo, C. J., Jackson, C. E., Lynch, H. T., Hruban, R. H., et al. (1996) · PubMed · Cited by 642

Flagged first, then by citations

Show all 39 references

Research works printed but not linked: 5

Lal G, 2000, Cancer Res, 60, 409
Tersmette AC, 2001, Clin Cancer Res, 7, 738
Murphy KM, 2002, Cancer Res, 62, 3789
Goggins M, 1996, Cancer Res, 56, 5360
Levy-Lahad E, 1997, Am J Hum Genet, 60, 1059

Sorted by citations

Pancreatic cancer
Mizrahi, J. D., Surana, R., Valle, J. W., & Shroff, R. T. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30974-0 · Cited by 2,559
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Tempero, M. A., Malafa, M. P., Al-Hawary, M. M., Behrman, S. W., Benson, A. B., Cardin, D. B., Chiorean, E. G., Chung, V. M., Czito, B. G., Chiaro, M. D., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0017 · Cited by 1,356
BRCAness revisited
Lord, C. J., & Ashworth, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.21 · Cited by 1,257
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Daly, M. B., Pal, T., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., Elkhanany, A. M., Friedman, S., Goggins, M., Hutton, M. L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0001 · Cited by 1,143
Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial
Aung, K. L., Fischer, S. E., Denroche, R. E., Jang, G.-H., Dodd, A., Creighton, S., Southwood, B., Liang, S.-B., Chadwick, D., Zhang, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2994 · Cited by 618
Self-citation
Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
Burstein, H. J., Krilov, L., Aragon‐Ching, J. B., Baxter, N. N., Chiorean, E. G., Chow, W. A., Groot, J. F. D., Devine, S. M., DuBois, S. G., El‐Deiry, W. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.5292 · Cited by 603
Genetics and biology of pancreatic ductal adenocarcinoma
Ying, H., Dey, P., Yao, W., Kimmelman, A. C., Draetta, G. F., Maitra, A., & DePinho, R. A. (2016) · Genes & Development · doi:10.1101/gad.275776.115 · Cited by 527
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020
Daly, M. B., Pilarski, R., Yurgelun, M. B. B., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., Elkhanany, A. M., Friedman, S., Garber, J. E., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0017 · Cited by 517
Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma
Shindo, K., Yu, J., Suenaga, M., Fesharakizadeh, S., Cho, C., Macgregor-Das, A., Siddiqui, A., Witmer, P. D., Tamura, K., Song, T. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.3502 · Cited by 458
The molecular biology of pancreatic adenocarcinoma: Translational challenges and clinical perspectives
Wang, S., Zheng, Y., Yang, F., Zhu, L., Zhu, X.-Q., Wang, Z.-F., Wu, X.-L., Zhou, C.-H., Yan, J.-Y., Hu, B.-Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00659-4 · Cited by 369
PD-1/PD-L1 and immunotherapy for pancreatic cancer
Feng, M., Xiong, G., Cao, Z., Yang, G., Zheng, S., Song, X., You, L., Zheng, L., Zhang, T., & Zhao, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.08.006 · Cited by 319
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
Qian, Y., Gong, Y., Fan, Z., Luo, G., Huang, Q., Deng, S., Cheng, H., Jin, K., Ni, Q., Yu, X., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00958-3 · Cited by 312
Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma
Connor, A. A., Denroche, R. E., Jang, G. H., Timms, L. E., Kalimuthu, S. N., Selander, I., McPherson, T. A., Wilson, G. W., Chan‐Seng‐Yue, M., Borozan, I., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3916 · Cited by 289
Self-citation
Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update
Sohal, D. P. S., Kennedy, E. B., Khorana, A. A., Copur, M. S., Crane, C. H., Garrido‐Laguna, I., Krishnamurthi, S., Moravek, C., O'Reilly, E. M., Philip, P. A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9636 · Cited by 279
PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications
Zhu, H., Wei, M., Xu, J., Hua, J., Chen, L., Meng, Q., Zhang, Y., Liu, J., Zhang, B., Yu, X., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01167-9 · Cited by 263
Overall survival results from the POLO trial: A Phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer
Kindler, H. L., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J. O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01604 · Cited by 244
Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer
Yurgelun, M. B., Chittenden, A. B., Morales-Oyarvide, V., Rubinson, D. A., Dunne, R. F., Kozak, M. M., Qian, Z. R., Welch, M. W., Brais, L. K., Da Silva, A., et al. (2019) · Genetics in Medicine · doi:10.1038/s41436-018-0009-5 · Cited by 217
An update on treatment options for pancreatic adenocarcinoma
Lambert, A., Schwarz, L., Borbath, I., Henry, A., Laethem, J. V., Malka, D., Ducreux, M. P., & Conroy, T. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919875568 · Cited by 222
DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives
Perkhofer, L., Gout, J., Roger, É., de Almeida, F. K., Simões, C., Wiesmüller, L., Seufferlein, T. T. W., & Kleger, A. (2020) · Gut · doi:10.1136/gutjnl-2019-319984 · Cited by 207
Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation
Wattenberg, M. M., Asch, D., Yu, S., O'Dwyer, P. J., Domchek, S. M., Nathanson, K. L., Rosen, M. A., Beatty, G. L., Siegelman, E. S., & Reiss, K. A. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0582-7 · Cited by 211
Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion
Stoffel, E. M., McKernin, S. E., Brand, R. E., Canto, M. I., Goggins, M., Moravek, C., Nagarajan, A., Petersen, G. M., Simeone, D. M., Yurgelun, M. B. B., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.01489 · Cited by 205
Identification of germline genetic mutations in patients with pancreatic cancer
Salo‐Mullen, E. E., O'Reilly, E. M., Kelsen, D. P., Ashraf, A. M., Lowery, M. A., Yu, K. H., Reidy‐Lagunes, D. L., Epstein, A. S., Lincoln, A., Saldia, A., et al. (2015) · Cancer · doi:10.1002/cncr.29664 · Cited by 198
Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance
Pettitt, S. J., Frankum, J. R., Punta, M., Lise, S., Alexander, J. J., Chen, Y., Yap, T. A., Haider, S. A., Tutt, A. N. J., & Lord, C. J. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1485 · Cited by 200
Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review
Kenner, B., Chari, S. T., Kelsen, D., Klimstra, D. S., Pandol, S. J., Rosenthal, M., Rustgi, A. K., Taylor, J. A., Yala, A., Abul-Husn, N., et al. (2021) · Pancreas · doi:10.1097/mpa.0000000000001762 · Cited by 158
Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma
Lowery, M. A., Kelsen, D. P., Capanu, M., Smith, S., Lee, J. W., Stadler, Z. K., Moore, M. J., Kindler, H. L., Golan, T., Segal, A., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.11.004 · Cited by 159
Self-citation
Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications
Hu, H.-F., Ye, Z., Qin, Y., Xu, X.-W., Yu, X.-J., Zhuo, Q.-F., & Ji, S.-R. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00584-2 · Cited by 149
Effects of mutations in Wnt/β-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity—Diverse effects on cell growth, metabolism and cancer
McCubrey, J. A., Rakus, D., Gizak, A., Steelman, L. S., Abrams, S. L., Lertpiriyapong, K., Fitzgerald, T. L., Yang, L. V., Montalto, G., Cervello, M., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.09.004 · Cited by 152
Current and Emerging Therapies in Metastatic Pancreatic Cancer
Manji, G. A., Olive, K. P., Saenger, Y. M., & Oberstein, P. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2319 · Cited by 145
Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history
Chaffee, K. G., Oberg, A. L., McWilliams, R. R., Majithia, N., Allen, B. A., Kidd, J., Singh, N., Hartman, A.-R., Wenstrup, R. J., & Petersen, G. M. (2018) · Genetics in Medicine · doi:10.1038/gim.2017.85 · Cited by 144
Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis
Casolino, R., Paiella, S., Azzolina, D., Beer, P. A., Corbo, V., Lorenzoni, G., Gregori, D., Golan, T., Braconi, C., Froeling, F. E. M., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03238 · Cited by 149
Pancreatic cancer in 2021: What you need to know to win
Tonini, V., & Zanni, M. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i35.5851 · Cited by 133
Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells
Pelosi, E., Castelli, G., & Testa, U. (2017) · Biomedicines · doi:10.3390/biomedicines5040065 · Cited by 128
Biodistribution of cisplatin revealed by imaging mass cytometry identifies extensive collagen binding in tumor and normal tissues
Chang, Q., Ornatsky, O., Siddiqui, I. F. S., Straus, R., Baranov, V. I., & Hedley, D. W. (2016) · Scientific Reports · doi:10.1038/srep36641 · Cited by 116
Self-citation
Therapeutic resistance of pancreatic cancer: Roadmap to its reversal
Yu, S., Zhang, C., & Xie, K. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188461 · Cited by 119
State of the art and future directions of pancreatic ductal adenocarcinoma therapy
Neuzillet, C., Tijeras‐Raballand, A., Bourget, P., Cros, J. F., Couvelard, A., Sauvanet, A., Vullierme, M., Tournigand, C., & Hammel, P. R. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.08.006 · Cited by 114
Galectin-3 Mediates Tumor Cell–Stroma Interactions by Activating Pancreatic Stellate Cells to Produce Cytokines via Integrin Signaling
Zhao, W., Ajani, J. A., Guha, S., Ochi, N., Hwang, R. F., Hafley, M., Johnson, R. L., Bresalier, R. S., Logsdon, C. D., Zhang, Z., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.12.014 · Cited by 106
Population genetic testing for cancer susceptibility: founder mutations to genomes
Foulkes, W. D., Knoppers, B. M., & Turnbull, C. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.173 · Cited by 105
Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer 2 ( BRCA2 ) Mutation
Du, C., Qi, Y., Zhang, Y., Wang, Y., Zhao, X., Min, H., Han, X., Lang, J., Qin, H., Shi, Q., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b01573 · Cited by 103
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer
Overman, M. J., Javle, M. M., Davis, R. E., Vats, P., Kumar‐Sinha, C., Xiao, L., Mettu, N. B., Parra, E. R., Benson, A. B., Lopez, C. D., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000587 · Cited by 97
Prognostic and predictive factors in pancreatic cancer
Dell’Aquila, E., Fulgenzi, C. A. M., Minelli, A., Citarella, F., Stellato, M., Pantano, F., Russano, M., Cursano, M. C., Napolitano, A., Zeppola, T., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27518 · Cited by 101
Systemic Therapy for Metastatic Pancreatic Cancer
Ettrich, T. J., & Seufferlein, T. T. W. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00895-4 · Cited by 94
Current Limitations and Novel Perspectives in Pancreatic Cancer Treatment
Robatel, S., & Schenk, M. (2022) · Cancers · doi:10.3390/cancers14040985 · Cited by 94
Genetics of familial and sporadic pancreatic cancer
Wood, L. D., Yurgelun, M. B., & Goggins, M. G. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.039 · Cited by 91
Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma
Brand, R. E., Borazanci, E. H., Speare, V., Dudley, B., Karloski, E., Peters, M. L. B., Stobie, L., Bahary, N., Zeh, H. J., Zureikat, A. H., et al. (2018) · Cancer · doi:10.1002/cncr.31628 · Cited by 88
Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair
Kausar, T., Schreiber, J. S., Karnak, D. M., Parsels, L. A., Parsels, J. D., Davis, M. A., Zhao, L., Maybaum, J., Lawrence, T. S., & Morgan, M. A. (2015) · Neoplasia · doi:10.1016/j.neo.2015.09.006 · Cited by 88
DNA damaging agents and DNA repair: From carcinogenesis to cancer therapy
de Almeida, L. C., Calil, F. A., Machado‐Neto, J. A., & Costa-Lotufo, L. V. (2020) · Cancer Genetics · doi:10.1016/j.cancergen.2020.12.002 · Cited by 88
BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma
Blair, A. B., Groot, V. P., Gemenetzis, G., Wei, J., Cameron, J. L., Weiss, M. J., Goggins, M., Wolfgang, C. L., Yu, J., & He, J. P. (2018) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2017.12.021 · Cited by 85
BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signaling
Shaashua, L., Ben-Shmuel, A., Pevsner-Fischer, M., Friedman, G., Levi-Galibov, O., Nandakumar, S., Barki, D., Nevo, R., Brown, L. E., Zhang, W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34081-3 · Cited by 79
Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer
Yarchoan, M. M., Myzak, M. C., Johnson, B. A., Jesus‐Acosta, A. D., Le, D. T., Jaffee, E. M., Azad, N. S., Donehower, R. C., Zheng, L., Oberstein, P. E., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17237 · Cited by 78
Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial
Golan, T., Kindler, H. L., Park, J. O., Reni, M., Macarulla, T. M., Hammel, P. R., Cutsem, E. V., Arnold, D., Hochhauser, D., McGuinness, D. H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01890 · Cited by 74
BRCA mutated pancreatic cancer: A change is coming
Rosen, M. N., Goodwin, R. A., & Vickers, M. M. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i17.1943 · Cited by 75
Germline mutations in Japanese familial pancreatic cancer patients
Takai, E., Yachida, S., Shimizu, K., Furuse, J., Kubo, E., Ohmoto, A., Suzuki, M., Hruban, R. H., Okusaka, T., Morizane, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12490 · Cited by 73
Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer
Kondo, T., Kanai, M., Kou, T., Sakuma, T., Mochizuki, H., Kamada, M., Nakatsui, M., Uza, N., Kodama, Y., Masui, T., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24865 · Cited by 72
Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma
Grant, R. C., Denroche, R. E., Jang, G. H., Nowak, K. M., Zhang, A. X. W., Borgida, A., Holter, S., Topham, J. T., Wilson, J. M., Dodd, A., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-320730 · Cited by 70
Self-citation
BRCA Share: A Collection of Clinical BRCA Gene Variants
Béroud, C., Letovsky, S. I., Braastad, C. D., Caputo, S. M., Beaudoux, O., Bignon, Y. J., Paillerets, B. B., Bronner, M., Buell, C. M., Collod‐Béroud, G., et al. (2016) · Human Mutation · doi:10.1002/humu.23113 · Cited by 67
BRCA-mutant pancreatic ductal adenocarcinoma
Lai, E., Ziranu, P., Spanu, D., Dubois, M., Pretta, A., Tolu, S., Camera, S., Liscia, N., Mariani, S., Persano, M., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01469-9 · Cited by 71
Screening and surveillance in hereditary gastrointestinal cancers: Recommendations from the European Society of Digestive Oncology (ESDO) expert discussion at the 20th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona, June 2018
Vangala, D., Cauchin, E., Balmañà, J., Wyrwicz, L. S., Cutsem, E. V., Güller, U., Castells, A., Carneiro, F., Hammel, P. R., Ducreux, M. P., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.09.004 · Cited by 66
Germline genetic variability in pancreatic cancer risk and prognosis
Gentiluomo, M., Canzian, F., Nicolini, A., Gemignani, F., Landi, S., & Campa, D. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.08.003 · Cited by 68
Cuproptosis-related gene index: A predictor for pancreatic cancer prognosis, immunotherapy efficacy, and chemosensitivity
Huang, X., Zhou, S., Liu, Y., Tóth, J., & András, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.978865 · Cited by 68
Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease
ter Veer, E., van Rijssen, L. B., Besselink, M. G., Mali, R. M. A., Berlin, J. D., Boeck, S. H., Bonnetain, F., Chau, I., Conroy, T., Cutsem, E. V., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30098-6 · Cited by 66
Prevalence of Germline Mutations Associated With Cancer Risk in Patients With Intraductal Papillary Mucinous Neoplasms
Skaro, M. F., Nanda, N., Gauthier, C. D., Felsenstein, M., Jiang, Z., Qiu, M., Shindo, K., Yu, J., Hutchings, D., Javed, A. A., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.254 · Cited by 65
Triangular Relationship between p53, Autophagy, and Chemotherapy Resistance
Xu, J., Patel, N. H., & Gewirtz, D. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238991 · Cited by 66
Progression to pancreatic ductal adenocarcinoma from pancreatic intraepithelial neoplasia: Results of a simulation model
Peters, M. L. B., Eckel, A. L., Mueller, P. P., Tramontano, A. C., Weaver, D. T., Lietz, A. P., Hur, C., Kong, C. Y., & Pandharipande, P. V. (2018) · Pancreatology · doi:10.1016/j.pan.2018.07.009 · Cited by 70
Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies
Pham, T. D., Shields, M. A., Spaulding, C., Principe, D. R., Li, B., Underwood, P. W., Trevino, J. G., Bentrem, D. J., & Munshi, H. G. (2021) · Cancers · doi:10.3390/cancers13030440 · Cited by 64
Universal Germline Genetic Testing for Hereditary Cancer Syndromes in Patients With Solid Tumor Cancer
Esplin, E. D., Nielsen, S. M., Bristow, S. L., Garber, J. E., Hampel, H., Rana, H. Q., Samadder, N. J., Shore, N. D., & Nussbaum, R. L. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00516 · Cited by 68
Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline BRCA or PALB2 Mutations
Reiss, K. A., Yu, S., Judy, R., Symecko, H., Nathanson, K. L., & Domchek, S. M. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00152 · Cited by 61
Multigene Hereditary Cancer Panels Reveal High-Risk Pancreatic Cancer Susceptibility Genes
Hu, C., LaDuca, H., Shimelis, H., Polley, E. C., Lilyquist, J., Hart, S. N., Na, J., Thomas, A., Lee, K. Y., Davis, B. T., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00291 · Cited by 57
Adolescent overweight and obesity and the risk for pancreatic cancer among men and women: a nationwide study of 1.79 million Israeli adolescents
Levi, Z., Rottenberg, Y., Twig, G., Katz, L. H., Leiba, A., Derazne, E., Tzur, D., Eizenstein, S., Keinan‐Boker, L., Afek, A. B., et al. (2018) · Cancer · doi:10.1002/cncr.31764 · Cited by 62
Pancreatic cancer screening in high-risk individuals with germline genetic mutations
Davee, T. R., Coronel, E. S., Papafragkakis, C., Thaiudom, S., Lanke, G., Chakinala, R. C., Nogueras‐González, G. M., Bhutani, M. S., Ross, W. A., Weston, B. R., et al. (2018) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2017.12.019 · Cited by 56
Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513
Chiorean, E. G., Guthrie, K. A., Philip, P. A., Swisher, E. M., Jalikis, F. G., Pishvaian, M. J., Berlin, J. D., Noel, M. S., Suga, J. M., Garrido‐Laguna, I., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1789 · Cited by 57
Pancreatic cancer as a sentinel for hereditary cancer predisposition
Young, E. L., Thompson, B. A., Neklason, D. W., Snow, A. K., Firpo, M. A., Werner, T. L., Bell, R., Sutherland, N., Smith, K. R., Berger, J., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4573-5 · Cited by 56
An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice
Rainone, M., Singh, I., Salo‐Mullen, E. E., Stadler, Z. K., & O'Reilly, E. M. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.5963 · Cited by 60
Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches
Şahin, İ. H., Lowery, M. A., Stadler, Z. K., Salo‐Mullen, E. E., Iacobuzio–Donahue, C. A., Kelsen, D. P., & O'Reilly, E. M. (2016) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1153424 · Cited by 56
Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma
Takeuchi, S., Doi, M., Ikari, N., Yamamoto, M., & Furukawa, T. (2018) · Scientific Reports · doi:10.1038/s41598-018-26526-x · Cited by 50
Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies
Покатаев, И. А., Fedyanin, M. Y., Максимовна, П. Е., As, P., Agafonova, J. A., Menshikova, S. F., Tryakin, A. A., Rumyantsev, А. А., & Tjulandin, S. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000578 · Cited by 50
Hereditary pancreatic cancer
Abe, K., Kitago, M., Kitagawa, Y., & Hirasawa, A. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-02015-6 · Cited by 62
Curing pancreatic cancer
Traub, B., Link, K. H., & Kornmann, M. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.030 · Cited by 51
Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis
Rebelatto, T. F., Falavigna, M., Pozzari, M., Spada, F., Cella, C. A., Laffi, A., Pellicori, S., & Fazio, N. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101895 · Cited by 50
Pancreatic Cancer Biomarkers: Oncogenic Mutations, Tissue and Liquid Biopsies, and Radiomics—A Review
Amaral, M. J., Oliveira, R. C., Donato, P., & Tralhão, J. G. (2023) · Digestive Diseases and Sciences · doi:10.1007/s10620-023-07904-6 · Cited by 50
Immunotherapy in pancreatic adenocarcinoma—overcoming barriers to response
Rosenberg, A. J., & Mahalingam, D. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.01.13 · Cited by 48
Germline mutations in pancreatic cancer and potential new therapeutic options
Pihlak, R., Valle, J. W., & McNamara, M. G. (2017) · Oncotarget · doi:10.18632/oncotarget.17291 · Cited by 48
Germline Variants and Risk for Pancreatic Cancer
Zhan, W., Shelton, C. A., Greer, P. J., Brand, R. E., & Whitcomb, D. C. (2018) · Pancreas · doi:10.1097/mpa.0000000000001136 · Cited by 50
Exome-Wide Association Study of Pancreatic Cancer Risk
Grant, R. C., Denroche, R. E., Borgida, A., Virtanen, C., Cook, N., Smith, A. L., Connor, A. A., Wilson, J. M., Peterson, G., Roberts, N. J., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.10.015 · Cited by 46
Self-citation
Biomarker-Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality?
Krantz, B. A., & O'Reilly, E. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3169 · Cited by 43
Inherited pancreatic cancer
Chen, F., Roberts, N. J., & Klein, A. P. (2017) · Chinese Clinical Oncology · doi:10.21037/cco.2017.12.04 · Cited by 42
Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer
Sailer, V., Eng, K., Zhang, T., Bareja, R., Pisapia, D. J., Sigaras, A., Bhinder, B., Romanel, A., Wilkes, D. C., Sticca, E., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00047 · Cited by 42
Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine
Costanzo, F. D., Costanzo, F. D., Antonuzzo, L., Mazza, E., & Giommoni, E. (2023) · Cancers · doi:10.3390/cancers15020416 · Cited by 42
Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening
Cremin, C., Lee, M. K. C., Hong, Q., Hoeschen, C., Mackenzie, A., Dixon, K., McCullum, M., Nuk, J., Kalloger, S. E., Karasinska, J. M., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.2973 · Cited by 41
High Prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer
Bannon, S. A., Montiel, M. F., Goldstein, J. B., Dong, W., Mork, M. E., Borras, E., Hasanov, M., Varadhachary, G. R., Maitra, A., Katz, M. H., et al. (2018) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-18-0014 · Cited by 40
Latest Advances in the Use of Therapeutic Focused Ultrasound in the Treatment of Pancreatic Cancer
Mouratidis, P., & ter Haar, G. (2022) · Cancers · doi:10.3390/cancers14030638 · Cited by 40
Substantial batch effects in TCGA exome sequences undermine pan-cancer analysis of germline variants
Rasnic, R., Brandes, N., Zuk, O., & Linial, M. (2019) · BMC Cancer · doi:10.1186/s12885-019-5994-5 · Cited by 39
Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study
Usón, P. L. S., Samadder, N. J., Riegert‐Johnson, D. L., Boardman, L., Borad, M. J., Ahn, D. H., Sonbol, M. B., Faigel, D. O., Fukami, N., Pannala, R., et al. (2021) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000414 · Cited by 41
Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies
Turpin, A., Neuzillet, C., Colle, E., Dusetti, N., Nicolle, R., Cros, J. F., de Mestier, L., Bachet, J., & Hammel, P. R. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221118019 · Cited by 41
Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications
Gupta, M., Iyer, R. V., & Fountzilas, C. K. (2019) · Cancers · doi:10.3390/cancers11121980 · Cited by 40
The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go
Thompson, E. D., Roberts, N. J., Wood, L. D., Eshleman, J. R., Goggins, M., Kern, S. E., Klein, A. P., & Hruban, R. H. (2020) · Modern Pathology · doi:10.1038/s41379-020-0629-6 · Cited by 41
Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review
Singh, R., Goldberg, J., Varghese, A. M., Yu, K. H., Park, W., & O'Reilly, E. M. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.03.003 · Cited by 38
S100A16 induces epithelial-mesenchymal transition in human PDAC cells and is a new therapeutic target for pancreatic cancer treatment that synergizes with gemcitabine
Li, T., Ren, T., Huang, C., Li, Y., Yang, P., Che, G., Luo, L., Chen, Y., Peng, S., Lin, Y., et al. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114396 · Cited by 37
Germline mutation prevalence in individuals with pancreatic cancer and a history of previous malignancy
Dudley, B., Karloski, E., Monzon, F. A., Singhi, A. D., Lincoln, S. E., Bahary, N., & Brand, R. E. (2018) · Cancer · doi:10.1002/cncr.31242 · Cited by 39
Hereditary Pancreatic Cancer Syndromes
Connor, A. A., & Gallinger, S. (2015) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2015.06.007 · Cited by 36
Self-citation

Authors: Holter, S., Borgida, A., Dodd, A., Grant, R., Semotiuk, K., Hedley, D., Dhani, N., Narod, S., Akbari, M., Moore, M., & Gallinger, S.
Affiliations: Mount Sinai Hospital (CA)
Spring Holter, Ayelet Borgida, Robert Grant, Kara Semotiuk, and Steven Gallinger, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital; Anna Dodd, David Hedley, Neesha Dhani, Malcolm Moore, and Steven Gallinger, McCain Pancreatic Cancer Centre, University Health Network; and Steven Narod and Mohammad Akbari, Women's College Research Institute, Toronto, Ontario, Canada.
ORCID: Borgida, Ayelet
Dodd, Anna
Grant, Robert
Semotiuk, Kara
Hedley, David
Dhani, Neesha
Narod, Steven
Akbari, Mohammad
Moore, Malcolm
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2015-10-01
Volume: 33
Issue: 28
Pages: 3124-3129
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2014.59.7401
OpenAlex: W2161479848
Cited by: 398
References: 39
Citations by year: 2026: 18 · 2025: 19 · 2024: 23 · 2023: 40 · 2022: 40 · 2021: 71 · 2020: 50 · 2019: 27 · 2018: 42 · 2017: 30 · 2016: 26 · 2015: 12
FWCI: 25.18
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: Canadian Cancer Society Research Institute
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords: germline BRCA1 mutation, germline BRCA2 mutation, pancreatic ductal adenocarcinoma, family history of cancer, Ashkenazi Jewish ancestry, hereditary cancer predisposition
MeSH terms: Adult, Aged, Aged, 80 and over, DNA Mutational Analysis, Female, Gene Frequency, Humans, Jews, Male, Middle Aged, Ontario, Pancreatic Neoplasms, Pedigree, Phenotype, Prognosis, Prospective Studies, Risk Factors, Incidence, Germ-Line Mutation, BRCA1 Protein, Genetic Predisposition to Disease, Carcinoma, Pancreatic Ductal, BRCA2 Protein, Heredity, Multiplex Polymerase Chain Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks